Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome.
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Pramipexole (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Adverse reactions; Registrational
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 22 May 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 14 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-000342-32).
- 14 Apr 2012 Planned number of patients changed from 116 to 120 as reported by European Clinical Trials Database.